Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04337970 · ClinicalTrials.gov registry record · Phase 1
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04337970: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04337970 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04337970, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes few or mild side effects when given in combination with a standard dose of axitinib.
Interventions
- DRUG Talazoparib
- DRUG Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-04-06 |
| Est. Completion | 2025-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04337970
The ClinicalTrials.gov registry entry for NCT04337970 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talazoparib is the first listed.
NCT04337970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04337970 about?
NCT04337970 is a clinical study titled "Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer". Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes few or mild side effects when ...
What is the current status of trial NCT04337970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-04-06. Estimated completion is 2025-05-23.
What interventions are being tested in trial NCT04337970?
The interventions under investigation include: Talazoparib (DRUG), Axitinib (DRUG).
Who is sponsoring clinical trial NCT04337970?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.